The present innovation, lipomer comprises asymmetric (irregular) lipid – polymer hybrid nanoparticles with glyceryl monostearate(gms) as lipid and gantrez an 119® as polymer. the asymmetric nanoparticles were readily prepared by a process of modified nanoprecipitation. the particle size of dh lipomer was ~ 400 nm and entrapment efficiency of dh was > 70%. stable lipomer formulation was optimized. lipomer could be freeze dried readily and supplied as sterile, apyrogenic, lyophilized product for intravenous injection, containing 500 mg of dh in a biocompatible nanoparticulate matrix, to be reconstituted with water for injection before administration. in vivo studies in animal models revealed high splenic uptake of dh lipomer in rats, rabbits and dogs. the spleen/liver ratios were 1.95± 0.98, 2.86 ± 1.31 and 6.77±2.52 respectively. clinical study in dogs suffering from clinical e. canis infection revealed significant improvement in clinical parameters- increase in platelet count, resolution of fever, absence of black-colored feces and regaining of appetite. dh lipomer i.v. revealed 83% efficacy at one-tenth dose while conventional dh formulation revealed 33% efficacy. more importantly enlarged spleen returned to normal size after treatment with dh lipomer.